Saturday, July 28, 2018
Hyatt Regency Tamaya Resort and Spa
Tamaya Ballroom FGH
Santa Ana Pueblo, NM
7:00 pm - 7:30 pm||Registration and Dinner
7:30 pm - 9:00 pm||CME-certified Symposium
Slide to view more
As clinical data emerge regarding the benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, obtaining access to these agents remains a barrier to their use. Given the high prevalence of patients on statin therapy who fail to meet low-density lipoprotein cholesterol (LDL-C) target goals, continuing education is crucial regarding the latest clinical advances and recommendations for the use of PCSK9 inhibitors, as well as practical strategies to gain access to these agents to improve patient outcomes. This educational activity will feature a panel of experts who will review the latest recommendations for the use of PCSK9 inhibitors in prevention and the impact of their use on cardiovascular outcomes. They will also assess the latest data on the benefits and safety of achieving low LDL-C goals, as well as detail practical strategies to improve access to treatment. Clinical cases will be presented to highlight the key educational objectives.